These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 6980569)

  • 41. 4-Hydroxy-3-nitro-phenylacetyl (NP)-specific T cell hybridomas.
    Cramer M; Mierau R; Takemori T; Suzuki G; Tada T
    Curr Top Microbiol Immunol; 1982; 100():69-77. PubMed ID: 7047084
    [No Abstract]   [Full Text] [Related]  

  • 42. Expression of cell surface antigens by suppressor T cell hybridomas. I. Comparison of phenotype and function.
    Trial J; Kapp JA; Pierce CW; Shreffler DC; Sorensen CM; Waltenbaugh C
    J Immunol; 1983 Feb; 130(2):565-72. PubMed ID: 6217244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses.
    Farrar JJ; Benjamin WR; Hilfiker ML; Howard M; Farrar WL; Fuller-Farrar J
    Immunol Rev; 1982; 63():129-66. PubMed ID: 7042543
    [No Abstract]   [Full Text] [Related]  

  • 44. LFA-1 but not Lyt-2 is associated with killing activity of cytotoxic T lymphocyte hybridomas.
    Kaufmann Y; Golstein P; Pierres M; Springer TA; Eshhar Z
    Nature; 1982 Nov; 300(5890):357-60. PubMed ID: 6983035
    [No Abstract]   [Full Text] [Related]  

  • 45. Idiotypic and fine specificity analysis of a (4-hydroxy-3-nitrophenyl)acetyl (NP)-specific suppressor T cell hybridoma at the level of cell surface structures, isolated receptor material and functional suppressor factor.
    Suzuki G; Cramer M; Hayakawa K; Okumura K; Tada T
    Eur J Immunol; 1983 Sep; 13(9):711-9. PubMed ID: 6225648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Modulation of the growth of murine thymoma cell lines having different Lyt-phenotypes by MDP and MDP(D-D): macrophage-mediated inhibition of in vitro cell growth.
    Phillips NC; Bahr GM; Modabber FZ; Chedid L
    Int J Immunopharmacol; 1984; 6(6):577-85. PubMed ID: 6334660
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of a human X mouse T cell hybridoma and identification of a clone secreting and binding interleukin-2.
    Durrant LG; Parkar M; Kenworthy N; Taylor GM
    Immunology; 1984 May; 52(1):117-28. PubMed ID: 6609121
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of Ia molecules in the activation of T lymphocytes. I. The activation of an IL 1-dependent IL 2-producing T cell hybridoma by Con A requires an interaction, which is not H-2-restricted, with an Ia-bearing accessory cell.
    Rock KL
    J Immunol; 1982 Oct; 129(4):1360-6. PubMed ID: 6809820
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of T cell hybridomas. II. Comparisons among three distinct types of monoclonal suppressor factors.
    Okuda K; Minami M; Furusawa M; Dorf ME
    J Exp Med; 1981 Dec; 154(6):1838-51. PubMed ID: 6172534
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of T cell hybridomas. I. Characterization of H-2 and Igh-restricted monoclonal suppressor factors.
    Minami M; Okuda K; Furusawa S; Benacerraf B; Dorf ME
    J Exp Med; 1981 Nov; 154(5):1390-402. PubMed ID: 6170719
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro generation of cytotoxic lymphocytes against radiation and radiation leukaemia virus-induced tumours. II. A radiation-induced thymoma generates cytyotoxic response in syngeneic but not in allogeneic lymphocytes.
    Yefenof E
    Immunology; 1980 Sep; 41(1):99-106. PubMed ID: 6448808
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of anti-tumor antibody in progressive tumor growth.
    Manson LA
    Transplant Proc; 1984 Apr; 16(2):524-7. PubMed ID: 6426105
    [No Abstract]   [Full Text] [Related]  

  • 53. Identification of gamma-interferon as a murine macrophage-activating factor for tumor cytotoxicity.
    Schreiber RD
    Contemp Top Immunobiol; 1984; 13():171-98. PubMed ID: 6428805
    [No Abstract]   [Full Text] [Related]  

  • 54. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Springer Semin Immunopathol; 1986; 9(1):51-71. PubMed ID: 3523804
    [No Abstract]   [Full Text] [Related]  

  • 55. Participation of lymphocyte activating factor (Interleukin 1) in the induction of cytotoxic T cell responses.
    Farrar WL; Mizel SB; Farrar JJ
    J Immunol; 1980 Mar; 124(3):1371-7. PubMed ID: 6153680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lymphocyte-induced macrophage cytotoxicity. Production of specific macrophage arming factor by sensitized Lyt 1+2+ T-lymphocytes.
    Pels E; De Weger RA; Den Otter W
    Int Arch Allergy Appl Immunol; 1984; 74(2):140-6. PubMed ID: 6609130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monoclonal cytotoxic T lymphocyte hybridomas capable of specific killing activity, antigenic responsiveness, and inducible interleukin secretion.
    Kaufmann Y; Berke G
    J Immunol; 1983 Jul; 131(1):50-6. PubMed ID: 6190926
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interleukin-2 dependent culture of cytolytic T cell lines.
    Gillis S; Watson J
    Immunol Rev; 1981; 54():81-109. PubMed ID: 7019041
    [No Abstract]   [Full Text] [Related]  

  • 59. T-lymphocytes.
    Lancet; 1982 Apr; 1(8275):778-9. PubMed ID: 6121229
    [No Abstract]   [Full Text] [Related]  

  • 60. Pillars article: Identification of a T cell-derived B cell growth factor distinct from interleukin 2. J. Exp. Med. 1982. 155: 914-923.
    Howard M; Farrar J; Hilfiker M; Johnson B; Takatsu K; Hamaoka T; Paul WE
    J Immunol; 2013 Feb; 190(3):864-73. PubMed ID: 23335802
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.